Our news

Dosing completed

All volunteers have now received three doses of 2AP01 (AAVLP-HPV), our very broad spectrum HPV vaccine formulated without adjuvant. The vaccine is well tolerated and no serious adverse events (SAEs)have been observed to date.
...

READ MORE

Article in MedWatch

Article about 2A Pharma in the Danish pharma/biotech media MedWatch (behind paywall):

Danish: https://medwatch.dk/secure/Medicinal___Biotek/article11272123.ece
English: https://medwatch.dk/secure/Top_picks_in_english/article11274345.ece

READ MORE

2A PHARMA INITIATES PHASE 1 CLINICAL TRIAL OF HPV VACCINE CANDIDATE

Malmö, Sweden – 13 March 2019
2A Pharma, the Swedish/Danish vaccine company today announced that, approximately 27 months after the company was founded, its novel, broad coverage, HPV L2 vaccine candidate formulated without...

READ MORE

2A PHARMA RECEIVES APPROVAL FOR PHASE 1 STUDY OF 2AP01

2A Pharma has received approval from the UK Medicines and Healthcare products Regulatory Authority and from the local Ethics Committee to proceed with a first-in-human study of 2AP01, which is beingdeveloped as broad coverage prophylactic HPV vaccine formulated without adjuvants. 2A Pharma expects that screening of volunteers will commence in January 2019 with first dosing in March 2019 and...

READ MORE

EUROSTARS FUNDING FOR THERAPEUTIC HEAD AND NECK CANCER VACCINE PROJECT

We are extremely pleased to announce that 2A Pharma in collaboration with partners from The Danish Technological Institute and Danish biotech company DNA Sense have been granted EUR 653,000 Eurostarsfunding for 2AP07 , a project to develop a therapeutic head and neck cancer vaccine.
...

READ MORE

SEE OUR PRESENTATION AT BIO EUROPE 2018 ON TUESDAY, 6 NOVEMBER AT 4.30PM

2A Pharma is very happy to announce that we will present at BIO Europe 2018.

Please join us on Tuesday, 6 November 2018 at 4.30pm in room B3 (level 0).

READ MORE

2A PHARMA SECURES SEK 20 MILLION OF FUNDING

2A Pharma is very pleased to announce that it has raised SEK 20 million (USD 2.2M) from existing and new investors. This funding augments the previously raised SEK 27 million (USD 3M) and will enable2A Pharma to drive its leading vaccine candidate, 2AP01, a broad coverage prophylactic HPV vaccine formulated without adjuvants, through phase 1 clinical studies and support progress of the...

READ MORE

MEET US AT THE WORLD VACCINE CONGRESS IN WASHINGTON, DC, USA, 3-5 APRIL 2018

READ MORE

BIO EUROPE SPRING 2018

2A Pharma is overwhelmed by the positive responses we received from potential partners and collaborators at BIO-Europe Spring 2018. The conference was a resounding success from our perspective and we are looking forward to continuing the many exciting conversations that were started.

READ MORE

PRESS RELEASE: 2A PHARMA AB RAISES SEK 27 MILLION AND SIGNS EXCLUSIVE WORLDWIDE LICENSE AGREEMENT

[pdf-embedder url="https://2apharma.com/wp-content/uploads/2018/10/2A-Pharma-AB-Press-Release-2017-01-16.pdf" title="2A Pharma AB Press Release 2017-01-16"]
Open PDF...

READ MORE